Back to EveryPatent.com
United States Patent | 6,096,312 |
Nakamura ,   et al. | August 1, 2000 |
An agent for preventing or treating AIDS which contains as its effective component an anti-Fas ligand antibody, and the method for preventing and treating AIDS by using such drug.
Inventors: | Nakamura; Norio (Tokyo, JP); Shirakawa; Kamon (Tokyo, JP); Matsusue; Tomokazu (Tokyo, JP); Nagata; Shigekazu (Suita, JP); Co; Man Sung (Cupertino, CA); Vasquez; Maximiliano (Palo Alto, CA) |
Assignee: | Mochida Pharmaceutical Co., Ltd. (Tokyo, JP); Osaka Bioscience Institute (Osaka-Fu, JP) |
Appl. No.: | 999631 |
Filed: | January 22, 1998 |
Jun 30, 1995[JP] | 7-188480 |
Current U.S. Class: | 424/145.1; 424/139.1; 424/148.1; 424/154.1; 424/172.1; 435/332 |
Intern'l Class: | A61K 039/395; C07K 014/525; C07K 016/00 |
Field of Search: | 424/145.1,148.1,154.1,172.1,139.1 435/322 530/388.2 |
5436154 | Jul., 1995 | Barbeti et al. | 435/240. |
5632994 | May., 1997 | Reed et al. | 424/198. |
5750653 | May., 1998 | Chu et al. | 530/350. |
Foreign Patent Documents | |||
0675200 | Oct., 1995 | EP. | |
2237935 | Sep., 1990 | JP. | |
8511692 | Dec., 1995 | JP. | |
9503672 | Apr., 1997 | JP. | |
9510540 | Apr., 1995 | WO. | |
9513293 | May., 1995 | WO. | |
9527735 | Oct., 1995 | WO. | |
9629350 A1 | Sep., 1996 | WO. | |
9712632 | Apr., 1997 | WO. |
Osband, Michael E. et al, Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today, vol. 11, No. 61990, pp. 193-195, 1990. Okurma, Yasushi. Research Report for 1997 Project for Promoting the AIDS Pharmaceuticals Development with English Translation. No vol, Journal or Pages cited. Yang, Yili. Blood, vol. 89, No. 2, Jan. 15, 1997; pp. 550-557. Estaquier, Jerome. Blood, vol. 87, No. 12, Jun. 15, 1996; pp. 4959-4966. Kovacs, Joseph A., M.D. New England Journal of Medicine, vol. 332, No. 9, 1995; pp. 567-575. |
______________________________________ Percentage of CD4.sup.+ T cells Before inoculation Day 8 Day 15 ______________________________________ Treatment group 28.7% 29.2% 14.1% Control group 29.7% 26.5% 6.9% ______________________________________